Sintilimab Injection Combined With Concurrent CCRT in Locally Advanced Esophageal Squamous Cell Carcinoma
Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
This study evaluated the effectiveness and safety of sintilimab combined with cCRT in
patients with locally advanced ESCC.
Phase:
Phase 2
Details
Lead Sponsor:
Sichuan Cancer Hospital and Research Institute
Collaborators:
Affiliated Hospital of Southwest Medical University Chongqing Three Gorges Central Hospital First Affiliated Hospital Xi'an Jiaotong University General Hospital of Ningxia Medical University